Find a Trial

Cardiovascular Clinical Trials

7 active studies and 17 selected completed trials. Search, filter by therapy area, and request a free pre-screen.

Participation in any clinical trial is voluntary and requires written informed consent reviewed by an Institutional Review Board (IRB) before any study procedure. You may withdraw at any time. Website content is informational and is not a substitute for medical advice from a licensed clinician.

Active trials

7 enrolling now

Showing all 7 trials

Sort

Phase 1/2Heart FailureActive — enrolling

VASA — Heart Failure with Preserved Ejection Fraction

Heart Failure with Preserved Ejection Fraction (HFpEF)

Study purpose: To evaluate the safety, tolerability, and biomarker profile of VS-041 in adults with Heart Failure with Preserved Ejection Fraction (HFpEF).
Who may qualify: Adults with heart failure and preserved ejection fraction (LVEF ≥ 50%) on stable medical therapy.
Commitment: Multiple in-clinic visits with safety and biomarker assessments; full schedule confirmed at screening.
Location: Amavita Research · North Miami Beach, FL

Sponsor: Vasa Therapeutics, Inc. · ClinicalTrials.gov ID: Ask our research team

Read more Apply for screening

Phase 2Heart FailureActive — enrolling

Pfizer C4921003 — PF-07328948 in HFpEF

Heart Failure with Preserved Ejection Fraction (HFpEF)

Study purpose: To evaluate PF-07328948, an oral BCKD kinase inhibitor, and the role of branched-chain amino acid catabolism in cardiac function in adults with heart failure with preserved ejection fraction (HFpEF).
Who may qualify: Adults with heart failure and preserved ejection fraction (LVEF ≥ 50%) on stable medical therapy.
Commitment: Scheduled clinic visits with metabolic, biomarker, and cardiac assessments; full schedule confirmed at screening.
Location: Amavita Research · North Miami Beach, FL

Sponsor: Pfizer · ClinicalTrials.gov ID: NCT06991257

Read more Apply for screening

Phase 3Heart FailureActive — enrolling

HERMES — Ziltivekimab in Heart Failure

Heart failure with mid-range or preserved ejection fraction and systemic inflammation

Study purpose: To evaluate whether ziltivekimab, an anti-IL-6 monoclonal antibody, improves outcomes in patients with heart failure and systemic inflammation.
Who may qualify: Adults with heart failure (mid-range or preserved ejection fraction) and laboratory evidence of systemic inflammation.
Commitment: Scheduled clinic visits with biomarker and cardiac assessments over the study period.
Location: Amavita Research · North Miami Beach, FL

Sponsor: Novo Nordisk · ClinicalTrials.gov ID: Ask our research team

Read more Apply for screening

Phase 2BHeart FailureActive — start-up

AnaCardio AC01 — Ghrelin Receptor Agonist in HFrEF

Heart Failure with Reduced Ejection Fraction (HFrEF)

Study purpose: To evaluate AC01, an oral ghrelin receptor agonist, in adults with chronic advanced heart failure with reduced ejection fraction (HFrEF) over a 12-week treatment period.
Who may qualify: Adults with chronic advanced heart failure and reduced ejection fraction (HFrEF) on stable medical therapy.
Commitment: 12-week treatment period with scheduled clinic visits; full schedule confirmed at screening.
Location: Amavita Research · North Miami Beach, FL

Sponsor: AnaCardio AB · ClinicalTrials.gov ID: NCT07584967

Read more Apply for screening

Phase 3Heart FailureActive — enrolling

ICONIC-HF — Ferric Derisomaltose in Iron-Deficiency Heart Failure

Iron-Deficiency Chronic Heart Failure

Study purpose: To evaluate whether intravenous ferric derisomaltose improves outcomes versus no intravenous iron in adults with symptomatic chronic heart failure and iron deficiency.
Who may qualify: Adults with chronic heart failure and lab-confirmed iron deficiency.
Commitment: Infusion visits and follow-up assessments over the study period.
Location: Amavita Research · North Miami Beach, FL

Sponsor: Pharmacosmos · ClinicalTrials.gov ID: NCT06929806

Read more Apply for screening

PivotalVascularActive — enrolling

GREAT — Golazo® Peripheral Atherectomy System

Peripheral Artery Disease

Study purpose: To evaluate the safety and effectiveness of the Golazo® Peripheral Atherectomy System in patients with peripheral artery disease.
Who may qualify: Adults 18+ with symptomatic peripheral artery disease (Rutherford Class 2–4) and a suitable target lesion on imaging.
Commitment: Procedure with structured post-procedure follow-up; details reviewed at screening.
Location: Advanced Cardiovascular of Miami (affiliated ASC) · Miami, FL

Sponsor: Avantec Vascular · ClinicalTrials.gov ID: NCT06321575

Read more Apply for screening

Recently Completed

Studies in close-out within the last 12 months. Full study summaries below.

Phase 3ACSRecently completed.

LIBREXIA-ACS (Janssen — Milvexian)

Phase 3 — Acute Coronary Syndrome

Sponsor: Janssen · Janssen 70033093ACS3003 · NCT05754957

Pivotal Phase 3 LIBREXIA-ACS study evaluating a novel antithrombotic strategy in patients following an acute coronary syndrome event. Recently completed.

View study summary

Phase 2Heart FailureEnrollment closed early in 2026 per sponsor decision.

JK07 (Salubris Biotherapeutics)

Phase 2 — Chronic Heart Failure

Sponsor: Salubris Biotherapeutics (JK07 Bio) · JK07.2.01 · NCT06369298

Enrollment closed early in 2026 per sponsor decision.

View study summary

Completed trials — selected

A selection of recent studies our team has executed across heart failure, ACS, hypertension, vascular, and cardiac imaging — covering sponsors from Boehringer Ingelheim, Novartis, Novo Nordisk, GE Healthcare, AngioDynamics, CSL Behring, Vifor, Cardurion, and more.

Phase 2Heart FailureCompleted2022–2024

CARDURION CRD-750-201 — Tovinontrine in HFrEF

Heart Failure with Reduced Ejection Fraction (HFrEF)

Cardurion CRD-750-201

Phase 2 study of tovinontrine, a PDE9 inhibitor, in HFrEF.

Sponsor: Cardurion Pharmaceuticals

Phase 2Heart FailureCompleted2022–2024

CARDURION CRD-750-202 — Tovinontrine in HFpEF

Heart Failure with Preserved Ejection Fraction (HFpEF)

Cardurion CRD-750-202

Phase 2 study of tovinontrine, a PDE9 inhibitor, in HFpEF.

Sponsor: Cardurion Pharmaceuticals

Phase 2Heart FailureCompleted2023–2024

R2R01 — Worsening Heart Failure

Worsening Heart Failure

R2R01-WHF-201

Sponsor: River 2 Renal

Phase 3Heart FailureCompleted2022–2024

HERMES — Ziltivekimab

Heart Failure with Preserved Ejection Fraction (HFpEF)

Novo Nordisk EX6018-4915

Phase 3 evaluation of ziltivekimab, an anti-IL-6 monoclonal antibody, in HFpEF.

Sponsor: Novo Nordisk

Phase 2Heart FailureCompleted(2024)

CARDINAL-HF (Cardurion — CRD-740)

Heart Failure

Cardurion CRD-740-201

Sponsor: Cardurion Pharmaceuticals

Heart FailureCompleted2022–2023

Cordio HearO — Voice Biomarker for HF

Heart Failure Decompensation Detection

Cordio CLN0011

Validation study of the Cordio HearO speech-based biomarker for early detection of heart failure decompensation.

Sponsor: Cordio Medical

Phase 3CardiologyCompleted2021–2023

GE Flurpiridaz F-18 — GE265-001

Myocardial Perfusion Imaging

GE Healthcare GE265-001

Sponsor: GE Healthcare

Phase 3CardiologyCompleted2022–2024

AURORA — Flurpiridaz F-18 — GE265-303

Myocardial Perfusion Imaging

GE Healthcare GE265-303

Sponsor: GE Healthcare

PivotalVascularCompleted2021–2023

Pathfinder I — AURYON EX-PAD-05

Peripheral Artery Disease

AngioDynamics EX-PAD-05

Pivotal Pathfinder I study of the AURYON Atherectomy + Thrombectomy system for peripheral artery disease.

Sponsor: AngioDynamics

Phase 3CardiologyCompleted2021–2022

COMET-Tail — Sotrovimab

COVID-19 (cardiovascular comorbidity cohort)

Vir/GSK VIR-7831-5008

Sponsor: Vir Biotechnology / GSK

Phase 3CardiologyCompleted2021–2022

ARISE — Bucillamine

Severe Cardiopulmonary Inflammation

Revive RT-003

Sponsor: Revive Therapeutics

Phase 3Heart FailureCompleted2020–2022

DIAMOND — Patiromer

Hyperkalemia in Heart Failure

Vifor PAT-CR-302

Phase 3 DIAMOND study of patiromer to enable RAASi therapy in HFrEF patients with hyperkalemia.

Sponsor: Vifor Pharma

Phase 3ACSCompleted2020–2023

CSL112 — ACS — CSL112_3001

Acute Coronary Syndrome

CSL Behring CSL112_3001

Phase 3 outcomes study of CSL112, a reconstituted human apolipoprotein A-I, post-acute coronary syndrome.

Sponsor: CSL Behring

Heart FailureCompleted2022–2023

ImpediMed Home Fluid Monitoring (HF)

Heart Failure Fluid-Status Monitoring

ImpediMed HF Study

Sponsor: ImpediMed

Phase 3Heart FailureCompleted2019–2021

EMPERIAL-preserved — Empagliflozin (HFpEF)

HFpEF — Exercise Capacity

Boehringer 1245-0167

Sponsor: Boehringer Ingelheim

Phase 3Heart FailureCompleted2019–2021

EMPERIAL-reduced — Empagliflozin (HFrEF)

HFrEF — Exercise Capacity

Boehringer 1245-0168

Sponsor: Boehringer Ingelheim

RegistryHeart FailureCompleted2018–2022

CHAMP-HF Registry — Sacubitril/Valsartan

Chronic Heart Failure (Registry)

Novartis CLCZ696BUS05

Real-world registry of sacubitril/valsartan utilization and outcomes in U.S. heart failure clinics.

Sponsor: Novartis

Sponsors: details on additional completed studies — including enrollment metrics, monitor reports, and audit history — are available on request under CDA. Request the full track record.